Boule Diagnostics AB

BOUL · Nasdaq Stockholm · Healthcare

2.41SEK +7.1%last day

Price as of 2 October 2026

The price over the past year, with dividends: −53.7%

Performance

1 month

−21.2%

1 year

−53.7%

3 years, per year

−36.1%

5 years, per year

−41.9%

Largest fall, 3 years

−83.6%

Below the peak now

−96.7%

Volatility, 1 year

52.7%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.5

Dividend yield

0.0%

Return on equity

−2.2%

Net margin

−0.8%

Market value

9 m USD

Quality, value and trend

Where Boule Diagnostics stands against every Nordic stock today. 100 is best.

Quality11

Profitability and a sound balance sheet over time. Better than 11% of Nordic stocks.

Value65

The price measured against earnings, assets and cash flow. Better than 65% of Nordic stocks.

Trend5

The price development over the past year. Better than 5% of Nordic stocks.

Combined10

Quality, value and trend together. Better than 10% of Nordic stocks.

About Boule Diagnostics

Boule Diagnostics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 200 employees.

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. It operates through Diagnostics and OEM Clinical Diagnostic Solutions. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis